BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11325842)

  • 1. Targeting dendritic cells to enhance DNA vaccine potency.
    You Z; Huang X; Hester J; Toh HC; Chen SY
    Cancer Res; 2001 May; 61(9):3704-11. PubMed ID: 11325842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
    Hauser H; Shen L; Gu QL; Krueger S; Chen SY
    Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.
    You Z; Huang XF; Hester J; Rollins L; Rooney C; Chen SY
    J Immunol; 2000 Oct; 165(8):4581-91. PubMed ID: 11035100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96.
    Yan J; Liu X; Wang Y; Jiang X; Liu H; Wang M; Zhu X; Wu M; Tien P
    J Gene Med; 2007 Feb; 9(2):107-21. PubMed ID: 17256801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
    Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
    Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccination: antigen presentation and the induction of immunity.
    Shedlock DJ; Weiner DB
    J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immortalized dendritic cell line with efficient cross-priming ability established from transgenic mice harboring the temperature-sensitive SV40 large T-antigen gene.
    Ebihara S; Endo S; Ito K; Ito Y; Akiyama K; Obinata M; Takai T
    J Biochem; 2004 Sep; 136(3):321-8. PubMed ID: 15598888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg.
    Huang Y; Chen Z; Jia H; Wu W; Zhong S; Zhou C
    Clin Immunol; 2006 Jun; 119(3):280-90. PubMed ID: 16531121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of priming cytotoxic T cell response and strategy for enhancing DNA vaccine potency in DNA immunization].
    Deng X; Cai M
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Mar; 20(1):175-9. PubMed ID: 12744193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
    Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
    J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N; King CA; Vitetta ES; Stevenson FK
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.